FDA's Top Q4 Blockbuster Drug Decisions

The FDA has some of its biggest decisions of the year looming in the next few months. The first new lupus drug in half a century, a blood-thinner with mega-blockbuster potential, controversial weight drugs and more are all up for regulatory decisions that can move markets and either throw a bucket of cold water or high octane gasoline on stock prices.

In every case, FierceBiotech has been following the deals and data every step of the way--from early-stage development right through to the NDA and deal-making phases. Now everyone faces the moment of truth, or at least a complete response letter.

The FDA's final decision may be signaled by an expert panel vote, but this is one area where there really is no sure thing. The agency has appeared to be taking a tough stance on safety, which has bedeviled some late-stage therapies. And its complete response letters are always opened with a mix of dread and hope. We've seen plenty of surprising decisions so far this year, and there will likely be more in the months ahead.

1. Benlysta - Human Genome Sciences and GlaxoSmithKline
2. Bydureon - Eli Lilly, Amylin Pharmaceuticals, Alkermes
3. Brilinta - AstraZeneca
4. Pradaxa - Boeringer Ingelheim
5. Qnexa - Vivus
6. Contrave - Orexigen
7. Ipilimumab - Bristol-Myers Squibb
8. Cladribine - Merck KGaA
9. Linjeta - Biodel
10. Afrezza - MannKind


Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.